You are here

savolitinib

AstraZeneca pushes forward with Tagrisso combos, touting PhII data with Hutchmed drug

Endpoints

Mon, 08/8/22 - 09:54 am

clinical trials

AstraZeneca dumps phase 3 renal cell carcinoma program

Fierce Biotech

Thu, 10/24/19 - 10:23 am

renal cell carcinoma

Chi-Med, AstraZeneca's savolitinib helps some Tagrisso-resistant EGFR lung cancer patients

Fierce Pharma

Sun, 03/31/19 - 03:44 pm

EGFR lung cancer